BioInvent International AB
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical needs. The Company's pipeline currently includes product candidates for the treatment of cancer, thrombosis and atherosclerosis. BioInvent is also running a number of early-stage clinical trials. Over the last ten years our research and development activities have led to the creation of several state-of-the-art in vitro, in vivo, and ex vivo disease model systems. These can be used to identify the therapeutically most efficacious and potent antibodies and to comprehensively monitor antibody safety and tolerability based on target disease biology and antibody mode of action.
Lund University - Sven-Erik Strand
Lund University and specifically the SRT (Systemic Radionuclide Therapy) research group has a long record of extensive use of radionuclides for diagnosis and therapy. The group consists of 2 professors, 2 senior researchers, 10 PhD students and one technician. The research is funded with approximately 6 million SEK per year from University Hospital, Swedish Research Council (VR) and Swedish Cancer Foundation. In 2008 the group was part of a larger constellation awarded a grant of 40 million SEK from the Wallenberg Foundation to build a bioimaging center including micro-PET/SPECT/CT, animal MR (9.4 T). The scientific outcome of the group is 5-10 papers per year. An extensive international collaboration is ongoing. The PI (Sven-Erik Strand) has been on sabbatical from 1991-1992 at Brookhaven National Lab, New York and 2005-2006 at UCLA, Los Angeles. The group is collaborating with several groups at Lund University and also with biomedical companies. This year the VR awarded the group a PhD position to be placed at one of these companies. In a recent external ranking of the research at the University the grading was 5.5 out of 6 (excellent to outstanding).
The Norwegian Radium Hospital - NRH
DNR and Rikshospitalets Comprehensive Cancer Center is one of Northern Europe’s largest. The institution has a large staff of research scientists within the fields of biophysics, biochemistry, molecular biology and tumor biology. The research departments contain several groups working with highly sophisticated technology and methods. Professor Eivind Hovig is the main contact person at DNR. He is heading a research group at DNR working with method development and molecular studies within cancer metastasis. A main focus is on gene therapy of melanoma. He also heads the bioinformatics activities at Rikshospitalet, and is affiliated with the Oslo node of “The Norwegian Microarray Consortium”.
Statistics for Innovation (SFI)
SFI is one of the 14 Norwegian Centers for Research-based Innovation, with the aim to enhance the capability of the Norwegian economy to innovate by focusing on long-term research, forging alliances between research-intensive enterprises and prominent research groups. SFI will develop core statistical methodologies, strategically necessary to achieve innovation goals in four key sectors: petroleum, finance, marine and health. The center has been in operations for eight years based at the Norwegian Computing Center/Norsk Regnesentral (NR) in Oslo.